Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...

Deutsche Bank placed at “Catalyst Call: Buy” on shares of Bio-Techne (TECH) as a short-term investment idea. The firm expects Bio-Techne to report fiscal Q3 results in line or above consensus ...

Evercore ISI initiated coverage of Bio-Techne (TECH) with an Outperform rating and $75 price target The firm believes that current volatility creates a “nice entry point” for Bio-Techne as ...

Bio-Techne Corporation ( NASDAQ:TECH ) shareholders might be concerned after seeing the share price drop 17% in ...

Bio-Techne Corp (NASDAQ:TECH) reported its Q4 2024 earnings, surpassing analyst expectations with an EPS of $0.42 against a forecast of $0.39. The company also reported revenue of $297 million ...

Bio-Techne Corp. TECH recently launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...

Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed ...

The $40m tower proposal was granted a planning permit by the Hobart City Council last year and the proponent, Techne Invest, which counts former AFL star Nick Riewoldt as one of its directors ...

Mirae Asset Global Investments Co. Ltd. raised its position in shares of Bio-Techne by 46.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,650 shares of the biotechnology ...

Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F ...